Concurrent abnormal non-acid reflux is associated with additional chronic rejection risk in lung transplant patients with increased acid exposure
Diseases of the Esophagus · 2024
DOI: 10.1093/dote/doae020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diseases of the Esophagus, 2024. Verfasst von Wai-Kit Lo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, MA, USA. Hauptthemen laut MEDLINE: Lung Transplantation, Graft Rejection, Gastroesophageal Reflux, Proportional Hazards Models. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIH.
Abstract (Originalsprache)
Acid reflux has been associated with allograft injury and rejection in lung transplant patients; however, the pathogenic role of non-acid reflux remains debated. We aimed to evaluate the impact of concurrent abnormal non-acid reflux with acid reflux on chronic rejection in lung transplant patients with acid reflux. This was a retrospective cohort study of lung transplant recipients who underwent pre-transplant combined impedance–pH study off acid suppression. Only subjects with acid exposure >4% were included. Non-acid reflux (pH > 4) episodes >27 was considered abnormal per prior normative studies. Chronic rejection was defined as chronic lung allograft dysfunction (CLAD) per International Society for Heart and Lung Transplantation criteria. Time-to-event analyses were performed using Cox proportional hazards and Kaplan–Maier methods, with censoring at death, anti-reflux surgery, or last follow-up. In total, 68 subjects (28 abnormal/40 normal non-acid reflux) met inclusion criteria for the study. Baseline demographic/clinical characteristics were similar between groups. Among this cohort of patients with increased acid exposure, subjects with concurrent abnormal non-acid reflux had significantly higher risk of CLAD than those without on Kaplan–Meier analysis (log-ranked P = 0.0269). On Cox multivariable regression analysis controlling for body mass index, age at transplantation, and proton pump inhibitor use, concurrent abnormal non-acid reflux remained independently predictive of increased CLAD risk (hazard ratio 2.31, confidence interval: 1.03–5.19, P = 0.04). Presence of concurrent abnormal non-acid reflux in lung transplant subjects with increased acid exposure is associated with additional risk of chronic rejection. Non-acid reflux may also contribute to pathogenicity in lung allograft injury/rejection, supporting a potential role for impedance-based testing in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, MA, USA.
- Division of Gastroenterology, Boston VA Healthcare System, Boston, MA, USA.
- Harvard Medical School, Boston, MA, USA.
- Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, USA.
ORCID-Profile: Walter W Chan
Förderung
- NHLBI NIH HHS
- NIH
Zitieren
APA
Lo, W. K., Muftah, M., Goldberg, H. J., Sharma, N., & Chan, W. W. (2024). Concurrent abnormal non-acid reflux is associated with additional chronic rejection risk in lung transplant patients with increased acid exposure. Diseases of the Esophagus. https://doi.org/10.1093/dote/doae020
Vancouver
Lo WK, Muftah M, Goldberg HJ, Sharma N, Chan WW. Concurrent abnormal non-acid reflux is associated with additional chronic rejection risk in lung transplant patients with increased acid exposure. Diseases of the Esophagus. 2024. doi:10.1093/dote/doae020
BibTeX
@article{Lo2024,
author = {Lo, Wai-Kit and Muftah, Mayssan and Goldberg, Hilary J and Sharma, Nirmal and Chan, Walter W},
title = {Concurrent abnormal non-acid reflux is associated with additional chronic rejection risk in lung transplant patients with increased acid exposure},
journal = {Diseases of the Esophagus},
year = {2024},
doi = {10.1093/dote/doae020}
}
EUVIMED